|
US5997680A
(en)
|
1996-04-30 |
1999-12-07 |
Avery Dennison Corporation |
Method of producing printed media
|
|
WO2000055318A2
(en)
*
|
1999-03-15 |
2000-09-21 |
University Of British Columbia |
Abc1 polypeptide and methods and reagents for modulating cholesterol levels
|
|
US6835563B1
(en)
|
1999-06-18 |
2004-12-28 |
Cv Therapeutics |
Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
|
|
AU1291901A
(en)
*
|
1999-09-01 |
2001-03-26 |
University Of British Columbia, The |
Compositions and methods for modulating hdl cholesterol and triglyceride levels
|
|
WO2001032184A2
(en)
*
|
1999-11-01 |
2001-05-10 |
Wisconsin Alumni Research Foundation |
Abc1 modulation for the modulation of cholesterol transport
|
|
US6555323B2
(en)
*
|
2000-02-08 |
2003-04-29 |
Pfizer Inc. |
Assay for ABCA1
|
|
CA2304906A1
(en)
|
2000-04-07 |
2001-10-07 |
1411198 Ontario Limited |
13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
|
|
US7378274B2
(en)
*
|
2000-05-02 |
2008-05-27 |
Aventis Pharma S.A. |
Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses
|
|
JP2004525611A
(ja)
*
|
2000-10-31 |
2004-08-26 |
アベンティス・ファーマ・ソシエテ・アノニム |
多型ヒトabca1遺伝子の配列、それらの使用、検出方法およびキット
|
|
FR2815970A1
(fr)
*
|
2000-10-31 |
2002-05-03 |
Aventis Pharma Sa |
Sequences polymorphes du gene humain abca1, leurs utilisations, les methodes et kits de detection
|
|
EP1203588A1
(de)
*
|
2000-11-06 |
2002-05-08 |
Bayer Ag |
Sterol-unabhängige Regulierung des ABC1 Promotors mit OncostatinM
|
|
CA2430697A1
(en)
*
|
2000-11-28 |
2002-12-12 |
Amgen, Inc. |
Atp-binding cassette transporter-like molecules and uses thereof
|
|
US20020169137A1
(en)
*
|
2001-02-09 |
2002-11-14 |
Active Pass Pharmaceuticals, Inc. |
Regulation of amyloid precursor protein expression by modification of ABC transporter expression or activity
|
|
US7033790B2
(en)
|
2001-04-03 |
2006-04-25 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
|
WO2002084301A2
(en)
*
|
2001-04-12 |
2002-10-24 |
Xenon Genetics, Inc. |
Screening assay for agents modulating activity of the abca1 protein
|
|
AU2002305019A1
(en)
*
|
2001-05-25 |
2002-12-09 |
University Of British Columbia |
Diagnostic methods for cardiovascular disease, low hdl-cholesterol levels, and high triglyceride levels
|
|
US20030125338A1
(en)
*
|
2001-06-12 |
2003-07-03 |
Active Pass Pharmaceuticals, Inc. |
Compounds, compositions and methods for modulating beta-amyloid production
|
|
US20030027301A1
(en)
*
|
2001-06-14 |
2003-02-06 |
Yi Hu |
Novel human transporter proteins and polynucleotides encoding the same
|
|
WO2003004692A2
(en)
*
|
2001-07-03 |
2003-01-16 |
Xenon Genetics, Inc. |
Screening processes for agents modulating cholesterol levels
|
|
US20030113728A1
(en)
*
|
2001-12-14 |
2003-06-19 |
Jukka Salonen |
Method for assessing the risk of cardiovascular disease
|
|
EP1575571A4
(de)
*
|
2002-01-02 |
2008-06-25 |
Genentech Inc |
Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
|
|
AU2003220521A1
(en)
*
|
2002-03-27 |
2003-10-13 |
Smithkline Beecham Corporation |
Methods of treatment with lxr modulators
|
|
JP2005522222A
(ja)
*
|
2002-04-18 |
2005-07-28 |
エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Atp結合性カセット遺伝子およびタンパク質の神経変性疾患に関する診断的および治療的使用
|
|
US7226771B2
(en)
|
2002-04-19 |
2007-06-05 |
Diversa Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
|
US20040033480A1
(en)
*
|
2002-08-15 |
2004-02-19 |
Wong Norman C.W. |
Use of resveratrol to regulate expression of apolipoprotein A1
|
|
US20050080024A1
(en)
*
|
2002-08-15 |
2005-04-14 |
Joseph Tucker |
Nitric oxide donating derivatives for the treatment of cardiovascular disorders
|
|
US20050080021A1
(en)
*
|
2002-08-15 |
2005-04-14 |
Joseph Tucker |
Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
|
|
FR2847266A1
(fr)
*
|
2002-11-15 |
2004-05-21 |
Genfit S A |
Methodes de criblage de composes modulant le flux de cholesterol et utilisations
|
|
US20050136421A1
(en)
*
|
2003-12-23 |
2005-06-23 |
Hayden Michael R. |
Methods and reagents for modulating cholesterol levels
|
|
EP1566202A1
(de)
*
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Verwendung von resistin-antagonisten zur behandlung von Rheumatoider arthritis
|
|
US7608413B1
(en)
*
|
2005-03-25 |
2009-10-27 |
Celera Corporation |
Kidney disease targets and uses thereof
|
|
AU2006249144B2
(en)
|
2005-05-18 |
2011-11-17 |
Ablynx Nv |
Improved NanobodiesTM against Tumor Necrosis Factor-alpha
|
|
LT2444424T
(lt)
|
2005-05-20 |
2018-10-25 |
Ablynx N.V. |
Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
|
|
JP4094660B1
(ja)
*
|
2005-08-10 |
2008-06-04 |
武田薬品工業株式会社 |
糖尿病治療剤
|
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
|
US8129197B2
(en)
*
|
2006-05-12 |
2012-03-06 |
SOLVO Biotechnológial ZRT. |
Cholesterol loaded insect cell membranes as test proteins
|
|
EP1892530A1
(de)
*
|
2006-08-25 |
2008-02-27 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Bestimmung der Transportaktivität eines Transportproteins
|
|
EP2057274B1
(de)
|
2006-09-21 |
2013-12-11 |
DSM IP Assets B.V. |
Phospholipase ,nukleinsaüre, die diese kodieren und verfahren zur ihrer herstellung und verwendung
|
|
ATE533783T1
(de)
|
2006-12-13 |
2011-12-15 |
Univ California |
Potente und selektive mittlersubstanzen von cholesterolefflux
|
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
CA2706425A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
US20110091462A1
(en)
|
2008-03-05 |
2011-04-21 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
MY188457A
(en)
|
2008-10-03 |
2021-12-10 |
Opko Curna Llc |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
WO2010065671A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
CA2745329C
(en)
|
2008-12-04 |
2022-07-12 |
Opko Curna, Llc |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
|
KR20110091796A
(ko)
|
2008-12-04 |
2011-08-12 |
오피케이오 큐알엔에이, 엘엘씨 |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
HUE026280T2
(en)
|
2009-02-12 |
2016-06-28 |
Curna Inc |
Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
|
|
EP2403873A1
(de)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
|
|
MX2011009751A
(es)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
|
|
US9708604B2
(en)
|
2009-03-17 |
2017-07-18 |
Curna, Inc. |
Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
|
|
WO2010120508A2
(en)
*
|
2009-03-31 |
2010-10-21 |
The General Hospital Corporation |
Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
|
EP2427554B1
(de)
|
2009-05-08 |
2016-11-16 |
CuRNA, Inc. |
Behandlung von dystrophin-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen die dmd-familie
|
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
|
KR101801407B1
(ko)
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
|
US9044493B2
(en)
|
2009-08-11 |
2015-06-02 |
Curna, Inc. |
Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
|
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
|
NO2480669T3
(de)
|
2009-09-25 |
2018-04-07 |
|
|
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
|
UA109884C2
(uk)
|
2009-10-16 |
2015-10-26 |
|
Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
|
|
UA111708C2
(uk)
|
2009-10-16 |
2016-06-10 |
Бандж Ойлз, Інк. |
Спосіб рафінування олії
|
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
|
EP2515947B1
(de)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
|
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
|
US8921334B2
(en)
|
2009-12-29 |
2014-12-30 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
|
|
ES2585829T3
(es)
|
2009-12-29 |
2016-10-10 |
Curna, Inc. |
Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
|
|
CA2785727C
(en)
|
2009-12-31 |
2020-01-07 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
|
NO2524039T3
(de)
|
2010-01-11 |
2018-04-28 |
|
|
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
|
CN102869777B
(zh)
|
2010-04-02 |
2018-11-02 |
库尔纳公司 |
通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
|
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
|
DK2576784T3
(en)
|
2010-05-26 |
2018-02-26 |
Curna Inc |
TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
|
|
WO2011150005A2
(en)
|
2010-05-26 |
2011-12-01 |
Opko Curna Llc |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
|
WO2012027601A2
(en)
|
2010-08-25 |
2012-03-01 |
The General Hospital Corporation |
Methods targeting mir-33 micrornas for regulating lipid metabolism
|
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
|
PY1147875A
(es)
|
2010-11-08 |
2015-08-03 |
Novartis Ag |
Polipéptidos de enlace de los receptores de quimiocina
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
EP3702460A1
(de)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycombassoziierte nichtcodierende rnas
|
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
|
US8987225B2
(en)
|
2010-11-23 |
2015-03-24 |
Curna, Inc. |
Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
|
|
WO2012170771A1
(en)
|
2011-06-09 |
2012-12-13 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
|
AU2012273928A1
(en)
|
2011-06-23 |
2014-02-06 |
Ablynx Nv |
Immunoglobulin single variable domains directed against IgE
|
|
KR101991980B1
(ko)
|
2011-09-06 |
2019-06-21 |
큐알엔에이, 인크. |
소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
|
|
ES2694592T3
(es)
|
2012-03-15 |
2018-12-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
CN104582737A
(zh)
*
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节apoa1和abca1表达的组合物和方法
|
|
US10017551B2
(en)
|
2013-03-15 |
2018-07-10 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
CA3006398A1
(en)
|
2015-11-27 |
2017-06-01 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
|
US11261260B2
(en)
|
2017-06-02 |
2022-03-01 |
Merck Patent Gmbh |
ADAMTS binding immunoglobulins
|
|
CN118085076A
(zh)
|
2017-06-02 |
2024-05-28 |
埃博灵克斯股份有限公司 |
结合聚集蛋白聚糖的免疫球蛋白
|
|
IL270951B2
(en)
|
2017-06-02 |
2025-05-01 |
Merck Patent Gmbh |
ADAMTS5, MMP13 and aggrecan-binding polypeptides
|
|
CN110997001A
(zh)
|
2017-06-02 |
2020-04-10 |
默克专利股份有限公司 |
Mmp13结合免疫球蛋白
|
|
CN115433733B
(zh)
|
2021-06-04 |
2025-12-12 |
生物岛实验室 |
环状RNA Circ-ACE2翻译的多肽及其应用
|
|
CN114369162B
(zh)
|
2021-12-28 |
2023-05-30 |
合肥天港免疫药物有限公司 |
抗体及其应用
|
|
JP2025523049A
(ja)
|
2022-07-14 |
2025-07-17 |
バイオ-テラ ソリュ-ションズ,エルティーディー. |
抗Nectin-4抗体及びその使用
|
|
AU2023313033A1
(en)
|
2022-07-27 |
2025-03-13 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
US20240415974A1
(en)
|
2022-12-23 |
2024-12-19 |
Ablynx N.V. |
Protein-based conjugation carriers
|
|
IL322519A
(en)
|
2023-02-17 |
2025-10-01 |
Ablynx Nv |
Polypeptides that bind to the neonatal fc receptor
|
|
CN122122303A
(zh)
|
2023-06-22 |
2026-05-29 |
阿布林克斯有限公司 |
用于调节细胞因子受体活性的嵌合蛋白
|
|
CN118027196B
(zh)
|
2023-06-25 |
2025-12-02 |
合肥天港免疫药物有限公司 |
抗cd3抗体及其应用
|
|
US20250034260A1
(en)
|
2023-07-05 |
2025-01-30 |
Sanofi |
Fcrn antagonists for treatment of igg-related diseases and disorders
|
|
KR20260068087A
(ko)
|
2023-09-04 |
2026-05-13 |
사노피 |
글리피칸-3-발현 종양의 치료에 사용하기 위한 폴리펩티드
|
|
CN119569886A
(zh)
|
2023-09-06 |
2025-03-07 |
合肥天港免疫药物有限公司 |
双特异性抗体及其应用
|
|
KR20250039299A
(ko)
|
2023-09-11 |
2025-03-20 |
노보 노르디스크 에이/에스 |
항-il-6 도메인 항체
|
|
WO2025061919A1
(en)
|
2023-09-22 |
2025-03-27 |
Ablynx Nv |
Bi- and multivalent albumin binders
|
|
CN122438859A
(zh)
|
2023-12-22 |
2026-07-21 |
阿布林克斯有限公司 |
用于核内递送的基于蛋白质的缀合载体
|
|
US20250236673A1
(en)
|
2023-12-22 |
2025-07-24 |
Ablynx N.V. |
Protein-based carriers for site-specific amine conjugation
|
|
TW202528354A
(zh)
|
2024-01-03 |
2025-07-16 |
中國商北京泰德製藥股份有限公司 |
B7-h3結合蛋白及其用途
|
|
TW202602933A
(zh)
|
2024-03-28 |
2026-01-16 |
美商健臻公司 |
與轉鐵蛋白受體1的特異性表位結合的多肽
|
|
CN121005780A
(zh)
|
2024-05-24 |
2025-11-25 |
合肥天港免疫药物有限公司 |
靶向hla-g的抗体或其抗原结合片段及其应用
|
|
WO2025262150A2
(en)
|
2024-06-18 |
2025-12-26 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026078159A1
(en)
|
2024-10-10 |
2026-04-16 |
Ablynx Nv |
Immune cell engagers and methods comprising the same
|